Methods for preparing...

Details Methods for preparing... Methods for preparing...

2007-01-30

2007-01-30

Crane, L. E. (Department: 1623)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C548S453000

Reexamination Certificate

active

10970641

ABSTRACT:
Disclosed are methods and intermediates for the preparation of 7-(2′-R1-substituted-β-D-ribofuranosyl)-4-amino-5-(optionally substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine compounds. These compounds are useful in treating viral infections caused by aflaviviridaefamily virus, such as hepatitis C virus. Such 7-(2′-substituted-β-D-ribofuranosyl)-4-amino-5-(optionally substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine compounds are represented by Formula I as follows:wherein, each of R1, R2, and R3are as defined herein.

REFERENCES:
patent: 4140851 (1979-02-01), Townsend et al.
patent: 4892865 (1990-01-01), Townsend et al.
patent: 4927830 (1990-05-01), Townsend et al.
patent: 4968686 (1990-11-01), Townsend et al.
patent: 4996206 (1991-02-01), Taylor et al.
patent: 5028608 (1991-07-01), Taylor et al.
patent: 5248775 (1993-09-01), Taylor et al.
patent: 5665721 (1997-09-01), Bhagwat et al.
patent: 5681941 (1997-10-01), Cook et al.
patent: 5763167 (1998-06-01), Conrad
patent: 5763597 (1998-06-01), Ugarkar et al.
patent: 5798340 (1998-08-01), Bischofberger et al.
patent: 5811534 (1998-09-01), Cook et al.
patent: 5824796 (1998-10-01), Petrie et al.
patent: 5844106 (1998-12-01), Seela et al.
patent: 5977332 (1999-11-01), Martin
patent: 6004939 (1999-12-01), Chen et al.
patent: 6054442 (2000-04-01), Chen et al.
patent: 6143749 (2000-11-01), Bhagwat et al.
patent: 6150510 (2000-11-01), Seela et al.
patent: 6211158 (2001-04-01), Seela et al.
patent: 6475985 (2002-11-01), Wagner et al.
patent: 6479651 (2002-11-01), Seela et al.
patent: 6593306 (2003-07-01), Chen et al.
patent: 6610847 (2003-08-01), Blumenkopf et al.
patent: 6635762 (2003-10-01), Blumenkopf et al.
patent: 6777395 (2004-08-01), Bhat et al.
patent: 6890929 (2005-05-01), Blumenkopf et al.
patent: 7094768 (2006-08-01), Roberts et al.
patent: 2002/0035077 (2002-03-01), Tam et al.
patent: 2003/0096981 (2003-05-01), Seela et al.
patent: 2003/0130226 (2003-07-01), Loakes et al.
patent: 2003/0153744 (2003-08-01), Mekouar et al.
patent: 2004/0014108 (2004-01-01), Eldrup et al.
patent: 2004/0014957 (2004-01-01), Eldrup et al.
patent: 2004/0067901 (2004-04-01), Bhat et al.
patent: 2004/0072788 (2004-04-01), Bhat et al.
patent: 61-229897 (1986-10-01), None
patent: WO/1991/10671 (1991-07-01), None
patent: WO/1994/18215 (1994-08-01), None
patent: WO/1994/24144 (1994-10-01), None
patent: WO/1995/07919 (1995-03-01), None
patent: WO/1997/49833 (1997-12-01), None
patent: WO/2001/90121 (2001-05-01), None
patent: WO/2001/72764 (2001-10-01), None
patent: WO/2002/18404 (2002-03-01), None
patent: WO/2002/057287 (2002-07-01), None
patent: WO/2002/057425 (2002-07-01), None
patent: WO/2003/051899 (2003-06-01), None
patent: WO/2003/055896 (2003-07-01), None
patent: WO/2003/061576 (2003-07-01), None
patent: WO/2003/068244 (2003-08-01), None
patent: WO2003/104420 (2003-12-01), None
patent: WO/2004/007512 (2004-01-01), None
patent: WO/2004/011478 (2004-02-01), None
patent: WO/2004/028481 (2004-04-01), None
patent: WO/2004/043977 (2004-05-01), None
Bergstrom, et al. “Antiviral Activity of C-5 Substituted Tubercidin Analouges”J. Med. Chem.27:285-292 (1984).
Hobbs, F.W. “alladium-Catalyzed Synthesis of Alkynylamino Nucleosides. A niversal Liner for Nucleic Acids”J. Org. Chem.54:3420-3422 (1989).
DeClercq, et al. “Nucleic Acid Related Compounds. 51. Synthesis and Biological Properties of Sugar-Modified Analogues of the Nucleoside Antibiotics Tubercidin, Toyocamycin, Sangivamycin, and Formycin”J. Med. Chem.30:481-486 (1987).
Bzowska et al., “7-Deazapurine 2′-deoxyribofuranosides are noncleavable competitive inhibitors ofEscherichia colipurine nucleoside phosphorylase (PNP),”Acta Biochimica Polonica, 45(3);755-768 (1998).
Seela et al., “Pyrrolo[2,3d]Pyrididine Nucleosides: 7-Deaza-2-2′-Deoxyadenosines,”Nucleosides, Nucleotides&Nucleic Acids, 19(1&2):237-251 (2000).
Migliaccio et al., “Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replicationin Vitro” J.Biol.Chem.278(49):49164-49170 (2003).
Carroll et al., “Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs”J.Biol. Chem278(14):11979-11981(2003).
Seela et al, “Oligonucleoties containing 7-deazaadenines: the influence of the 7-substituent chain length and charge on the duplex stability,”Helvetica Cimica Acta., 82(11):1878-1898 (1999).
Rosemeyer, et al., “Stereoelectronic effects of modified purine bases on the sugar conformation of nucleosides: pyrrolo[2,3-d] pyrimidines,”Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry, 11:2341-2346 (1997).
Rosemeyer, et al., “Steric and stereoelectronic effects of 7-deazapurine bases on the sugar conformation of 2′-deoxynucleosides”Nucleosides&Nucleotides16(7-9) 1447-1451 (1997).
Rosemeyer, et al., “Stereoelectronic effects of modified purines on the sugar conformation of nucleosides and fluorescence properties,”Nucleosides&Nucleotides, 16(5&6):821-828 (1997).
Seela, et al., “Palladium-catalyzed cross coupling of 7-iodo-2′-deoxytubercidin with terminal alkynes”Synthesis6:726-730 (1996).
Schneller, et al., “Biological Activity and a modified synthesis of 8-Amino-3-β-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, and isomer of formycin,”J. Med Chem.27, 924-928 (1984).
Giziewicz, et al., “Antiviral and antimetabolic activities of formycin and its N-, N2-, 2′-O- and 3′-O-methylated derivatives,”Biochemical Pharmacology24, 1813-1817, (1975).
Bergstrom, et al., Pyrrolo[2,3-d]pyrimidine Nucleoside Antibiotic Analogues. Synthesis via Organopalladium Intermediates Derived from 5-Mercuritubercidin,J. Org Chem.46:1423-1431 (1981).
Sharma, et al., “Synthesis of 5′-Substituted Derivatives of the Pyrrolo [2,3-d]-Pyrimidine Nucleoside Sangivamycin and their Effect on Protein Kinase A and C Activity,”Nucleosides&Nucleotides12(3&4) 295-304 (1993).
Müller, et al., “7-Deaza-2-phenyladenines: Structure-Activity Relationship of Potent A1 Selective Adenosine Receptor Antogonists” J. Med. Chem. 33:2822-2828 (1990).
Limori, et al., “2′-C-, 3′-C- and 5′-C-Methylsanglvamycins: Conformational Lock With The Methyl Group,” Tetrahedrom Letters 32(49) 7273-7276 (1991).
Kondo, et al., “Synthesis of 5-Methyltubercidin and Its α-Anomer via Condensation of the Anion of 4-Methoxy-5-methyl-2-methylthiopyrrolo [2, 3-d] pyrimidine and 2, 3,5-Tri-O-benzyl-D-ribofuranosyl Bromide,”Agric.Biol. Chem.41(8):1501-1507 (1977).
Uematsu, et al., “5-Hydroxymethyltubercidin, Synthesis, Biological Activity, and Role in Pyrrolopyrimidine Biosynthesis,” J. of Med.Chem, 16(12):1405-1407(1973).
Schram, et al., “Pyrrolopyrimidine Nucleosides VIII. Synthesis of Sangivamycin Derivatives possessing exocyclic heterocycles at C 5”J. Carbohydrates, Nucleosides, Nucleotides1(1):39-54 (1974).
Murai et al. “A Synthesis and an X-Ray Analysis of 2′-C,3′-C- And 5′-C-Methylsangivamycins”Heterocycles33:391-404 (1992).
Beigelman et al. “New Syntheses of 2′-C-Methylnucleosides Starting from D-Glucose and D-Ribose”Carbo. Research, 166:219-232 (1987).
Bio et al. “Practical Synthesis of a Potent Hepatitis C Virus RNA Replication Inhibitor”J. Org. Chem.(2004) 69:6257-6266, WEB published on Aug. 13, 2004.

Affiliated with

Also associated with

Rating

Methods for preparing... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for preparing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for preparing... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3745126